Mizuho Securities Raises Price Target on Urban Outfitters (URBN) Following a 4Q EPS Beat

Brean Capital Reiterates Buy Following Urban Outfitters' (URBN) Better-Than-Expected 4Q

Brean Capital reiterated a Buy rating on Urban Outfitters, Inc. (NASDAQ: URBN), and raised the price target to $35.00 (from $32.00), following the company's 4Q earnings report. URBN reported earnings of $0.61, beating the consensus estimate of $0.56. The beat was due to better-than-expected improvement in GM, and lower share count with 4.3m shares repurchased/retired... More

Wedbush Remains Sidelined on Urban Outfitters (URBN) as Margins Drive 4Q Upside

Wedbush reiterated a Neutral rating on Urban Outfitters, Inc. (NASDAQ: URBN), and raised the price target to $32.00 (from $23.00), following the company's 4Q earnings report. URBN reported 4Q upside on better than expected merchandise margins from the Urban division. CEO Hayne discussed the... More

UPDATE: Stifel Boosts PT on Urban Outfitters (URBN) to $34 Following Q4 Results; Sees Strong Start to Q1

(Updated - March 8, 2016 9:19 AM EST)

Stifel reaffirms Urban Outfitters (Nasdaq: URBN) at Buy. but lifts its price target from $30 to $34 following strong Q4 earnings results issued Monday night.

Analyst Richard Jaffe noted weakness in apparel sales for the quarter driven by a lack of consumer... More

Cowen Raises Price Target on Urban Outfitters (URBN) to $33 Following 4Q

Cowen reiterated a Market Perform rating on Urban Outfitters, Inc. (NASDAQ: URBN), and raised the price target to $33.00 (from $25.00), following the company's 4Q. Stock could trade +HSD on 4Q EPS beat.

Analyst Oliver Chen commented, "Value Creation Thru Speedier Supply Chain, Renewed Customer Focus,... More

After-Hours Stock Movers 03/07: (XNCR) (LNCO) (URBN) Higher; (ACRX) (SHAK) (ILMN) Lower (more...)

Xencor, Inc. (NASDAQ: XNCR) 30.4% HIGHER; announced dosing the first patient in a Phase 2 trial of XmAb®5871 in patients with IgG4-Related Disease (IgG4-RD). The Company also announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with Systemic Lupus Erythematosus (SLE).

Linn Co, LLC (NASDAQ: LNCO) 14.6% HIGHER; adds to recent gains, including today's 109% surge.

AcelRx Pharma (NASDAQ: ACRX) 12.5% LOWER; reported Q4 EPS of ($0.24), $0.14... More

UPDATE: Urban Outfitters (URBN) Tops Q4 EPS by 5c

(Updated - March 7, 2016 4:10 PM EST)

Urban Outfitters (NASDAQ: URBN) reported Q4 EPS of $0.61, versus the analyst estimate of $0.56. Revenue for the quarter came in at $1.01 billion versus the consensus estimate of $1.02 billion.

For earnings history and earnings-related data on Urban Outfitters (URBN) click here.